Detection of asymptomatic Leishmania infection in Bangladesh by novel antigen and antibody diagnostic tools shows strong association with PKDL patients

Study ethics

This study was approved by the Ethical Review Committee (ERC) of the ICDDR,B (PR-14093). Adult participants provided written informed consent, and in the case of any participants under 18 years of age, a parent or guardian provided informed consent.

Asymptomatic visceral leishmaniasis clinical samples

Blood and urine samples from 720 clinically healthy household and neighbouring contacts in adjacent households of 276 VL or PKDL index cases (between 1 and 8 contacts per index case), aged 5 to 60 years, with no symptoms or history of VL and PKDL, were collected between September 2016 and March 2018. The study was conducted in the VL endemic districts of Mymensingh, Gazipur, Tangail, Narail, Jamalpur, Pabna, and Brahmanbaria in Bangladesh. Symptoms considered included presence of fever, rash, loss of appetite, weight loss, lymph node enlargement, abdominal enlargement and pain. Demographic and clinical parameters were recorded. Samples were transported to Dhaka using a cold chain for processing and laboratory analysis using DAT and LAMP. Urine and DNA samples for Leishmania antigen ELISA and qPCR respectively were transported on ice to the UK from Bangladesh and stored at -20°C until testing.

DNA extraction

DNA was extracted in three different ways: 1. DNA was extracted from 100μl whole blood and eluted in 200μl buffer using DNeasy blood and tissue DNA extraction kits (Qiagen, Hilden, Germany) as per the manufacturer’s instructions. 2. Boil and spin extractions were carried out by pre-treating whole blood samples with SDS. Briefly, 10% SDS solution was mixed with blood to a final concentration of 5% and stored at -20°C. Once defrosted, samples were inverted 10 times and allowed to stand at room temperature for 10 minutes. Samples were further inverted and 400μl of distilled water were added before incubation at 90°C for 10 minutes. Tubes were then centrifuged at maximum speed for 3 min and the supernatants stored for testing. 3. DNA was extracted from dried blood spots (DBS). Whole blood was air-dried onto Whatman filter paper (GE Healthcare Life Sciences, Buckinghamshire, UK) for 30 min at room temperature and stored in individual bags. Discs of 7mm were punched out of the paper and added to an Eppendorf with 50μl of double-distilled water. Tubes were incubated at 90°C for 10 minutes followed by centrifugation for 3 minutes at maximum speed. Supernatants were stored at -20°C for testing.

qPCR

Real time PCR (qPCR) was performed on DNA extracted from whole blood using Qiagen DNeasy kits (Qiagen, Germany) [18]. A 1.25 μL volume of DNA was added to 11.25 μL amplification mixture containing 2.5 μL QuantiFast mastermix (Qiagen, Germany), 0.4 μM kDNA forward primer, 0.4 μM kDNA reverse primer, and 0.2 μM kDNA FAM-probe. Amplification was performed on a Qiagen Rotor-Gene Q system with following reaction conditions: 5 min at 95°C, followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C. Data was analysed using the Rotor-Gene Q series software (Qiagen, Germany). Standard curve analysis was performed using Leishmania donovani DNA (positive control) and data was used to set a qPCR threshold. Samples with cycle threshold (Ct) <34 were considered positive.

Loop mediated isothermal amplification (LAMP)

LAMP was run on DNA extracted from whole blood using the DNeasy blood and tissue DNA extraction kits (Qiagen, Germany), boil and spin extraction, and extraction from dried blood spots as described above. Loopamp™ Leishmania Detection kits (Eiken Chemical Co., Ltd, Tokyo, Japan) were used. Samples to be tested were made up to total volume of 30μl by adding 3μl DNA sample to 27μl of water. The lids of the tubes were then closed, and the sample mixed with the master mix contained in the tube cap by inverting the tubes and leaving to stand for 2 minutes cap-side down. The tubes were inverted 5 times, spun down and incubated at 65°C for 40 minutes, then 80°C for 5 minutes. Results were visualized under blue LED light illumination, using the Fluorescence Visual Check Unit of the HumaLoop M incubator (HUMAN, Wiesbaden, Germany). Results were read by two technicians blinded to each other. A third technician was used in the event of disagreement and the majority used.

Direct agglutination test (DAT)

The DAT was carried out in Bangladesh and performed as previously described [20].

Following a dilution of sera 1:100, the samples were further diluted in eight two-fold serial dilutions. Where samples did not react in the first dilution, the end titer was read as <1:200. Where samples still reacted at the final dilution, the end titer was read as >1:25,600. The threshold for a positive DAT result was set at >1:1600 as previously used by Hasker et al. for detection of asymptomatic infection [20].

Leishmania antigen ELISA

The Leishmania antigen ELISA (Clin-Tech., Guilford, UK) was performed on urine samples as per the manufacturer’s instruction. Briefly, samples were diluted 1 in 20 with assay diluent. 100μl ofantigen calibrators and diluted samples were added to a pre-coated 96-well plate and incubated at 37°C for 30 minutes. Following 4 washes, 100μl of working strength tracer was added to the wells and incubated at 37°C for 30 minutes. Following a further 4 washes, 100μl of TMB substrate was added to each well and incubated uncovered between 18° and 25°C for 30 minutes. 100μl of stop solution was then added to each well. A standard curve was included on each plate. The optical densities (OD) were read at 450nm and blanked on air or with the 620nm reading within 30 minutes of addition of stop solution. Four parameter curve fitting software was used to calculate the concentration (UAU/ml) of each sample. IBM SPSS Statistics 24 was used to generate receiver- operating characteristic (ROC) curves using 720 asymptomatic cases and 80 VL cases to determine the threshold in UAU/ml that gave a sensitivity of 98.8% and a specificity of 96.7%. The area under the curve (AUC) was calculated.

Statistical analysis

Data were analysed in R Studio Version 1.1.456. Discrete variables were summarised as counts and percentages. Continuous variables were summarised as the median and interquartile range (IQR). The software package ‘Venny’ was used to create Venn diagrams for comparison of diagnostic tests [21].

Percentage agreement between diagnostic tests and Cohen’s kappa (k) statistics with p-values to measure agreement between diagnostic tests were calculated with the irr package version 0.84.1 in R. Logistic regression was used to regress asymptomatic L. donovani infection (defined as positive for at least one of the four tests) outcome variable onto potential risk factor variables identified in the literature. Latent class analysis was used to estimate diagnostic accuracy and prevalence [22], Test results were assumed to be conditionally dependent, with Bayesian prior distributions on sensitivity, specificity and prevalence set using Betabuster 1.0 (https://betabuster.software.informer.com/). The analysis was implemented in R Studio Version 1.1.456 using the ‘IcaR’ model written by Jonathan Marshall (version 2bc8ca6, 13^th November 2015) [23].

Study population

A total of 720 individuals were sampled, of those 280 (38.9%) were male with a median age of 27 (IQR = 25). Most common occupations were students (34.4%) and housewives (41.9%). A total of 505 (70.1%) contacts lived within the household of an index case and 215 (29.9%) lived within a neighbouring household.

A total of 69 individuals were positive for at least one diagnostic test. Of those, 31 (44.9%) were male with a median age of 30 (IQR = 25). Most common occupations within the 69 individuals were students (33.3%) and housewives (37.7%). 50 (72.5%) lived within the household of an index case. The 69 asymptomatic cases were spread across 59 (21.4%) of the 276 index cases. Of those 69 index cases, median percentage positivity of the contacts was 33.3% (IQR = 25).

The 720 contacts were associated with VL cases (66.1%) - made up of new VL cases (90.1%), relapsed VL (9.5%), VL treatment failure (0.4%) - or PKDL cases (33.9%) (Table 1). Of the 242 PKDL index cases with known rash type, 230 (95.0%) presented with macular rash, 4 (1.7%) with macular and papular rash, 6 (2.5%) with nodular and macular rash, and 2 (0.8%) with macular, nodular and papular rash (Table 1). The 69 asymptomatic cases were associated with new VL cases (49.3%) or PKDL cases (50.7%), with the majority of such PKDL cases presenting with macular rash (94.3%) (Table 1).

Estimates of asymptomatic infection in contacts of index cases using tests to detect active infection

Of the 720 participants screened, 69 (9.6%) were positive by at least one test. Of the 720 asymptomatic DNA samples screened, 7 (1.0%) were positive by kDNA qPCR, with a mean Ct value of 31.9 (range 26.7 - 33.9). Urine samples were screened with the Leishmania antigen ELISA, of which 24 (3.3%) were found to be positive. Samples screened by DAT were considered positive at a titer of ≥1:1600. A total of 28 (3.9%) samples were found to be DAT positive, 11 (39.3%) of which had a titer ≥1:12,800. LAMP detected 6 (0.8%), 8 (1.1%), and 3 (0.4%) asymptomatic infections when DNA was extracted using Qiagen kits, boil and spin, and from DBS, respectively. For the purposes of further analysis, a participant with a positive LAMP result from any one of the three extraction techniques was considered LAMP positive, of which there were 15 (2.1%).

Leishmania antigen ELISA and the DAT identified the highest proportion of positive subjects. Only 1 (0.1%) subject was identified as positive by all 4 diagnostic methods, 2 (0.3%) were identified by 2 diagnostic methods, and 66 (9.2%) were identified by 1 diagnostic method only. In the 69 asymptomatic participants, 26 (37.7%) were positive by DAT only and 6 (8.7%) were positive by qPCR only. Of the 24 (34.8%) participants positive by ELISA, 3 (4.3%) were positive by at least one other test (Fig 1). Generally, poor agreement was found between tests. However, antigen and molecular tests showed better agreement in combination compared to the same tests in combination with serology (Table 2). In combination, the DAT and Leishmania antigen ELISA capture all participants positive by more than 1 of the 4 tests.

• Download figure
• Open in new tab

Fig 1. Asymptomatic infection was detected in 69 (9.6%) contacts by a combination of four diagnostic tests.

DAT was positive in 28 (40.6%) participants, 26 (37.7%) of whom were positive for DAT alone, 11/28 (39.3%) of whom had a titer greater than 1:12,800. QPCR was positive in 7 (10.1%) participants, 6 (8.7%) of whom were positive for qPCR alone. LAMP was positive in 15 (21.7%) participants, 13 (18.8%) of whom were positive for LAMP alone. Leishmania antigen ELISA was positive in 24 (34.8%) participants, of whom 21 (30.4%) were positive for ELISA alone and 3 (4.3%) were positive by ELISA and at least 1 other test.

Risk factors for asymptomatic VL

Logistic regression was used to confirm risk factors associated with being positive for at least one of the four diagnostic tests. Age, gender, occupation, and living within the index household compared to neighbouring household were not found to be associated with asymptomatic infection. The index case being a PKDL case (OR 1.94, p = 0.009), specifically macular PKDL (OR 2.12, p = 0.004) were found to be significantly associated with being positive by at least one of the four tests.

Latent class analysis to estimate disease state and diagnostic accuracy in the absence of a gold standard

In the absence of a single reference standard or a composite reference standard, latent class analysis (LCA) was used to estimate disease state. LCA estimated qPCR, LAMP, DAT, and Leishmania antigen ELISA to have sensitivities (2.5 - 97.5 percentiles) of 85.6% (55.1 - 99.5), 99.8% (99.2 - 99.9), 97.5% (90.5 - 99.9), and 98.9% (96.2 - 99.9) and specificities of 96.1% (94.7 - 97.5), 96.7% (95.3 - 97.8), 99.0% (98.1 - 99.6), and 97.9% (96.7 - 98.9), respectively. Prevalence of L. donovani asymptomatic infection in VL and PKDL contacts in Bangladesh was estimated to be 0.3% (0.03 - 0.7).